ADC Therapeutics SA (ADCT) Misses Q1 EPS by 57c

ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.53), $0.57 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $18.99 million versus the consensus estimate of $20.29 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
• XP Inc eyes US banking license as next business step
• XP Inc. (XP) Tops Q2 EPS by 8c